Cinryze: hereditary angioedema treatment

Cinryze, a C1-esterase inhibitor product derived from human plasma, is indicated for patients with hereditary angioedema.

Cinryze: a C1-esterase inhibitor for treatment and prophylaxis of hereditary angioedema
Cinryze: a C1-esterase inhibitor for treatment and prophylaxis of hereditary angioedema

In addition to being licensed for the treatment of acute attacks, Cinryze is also licensed for pre-procedure prevention and for routine prevention when oral prevention or repeat acute treatment is inadequate or not tolerated.

Clinical studies

In an open-label study involving 91 procedures (medical, dental or surgical) in 41 patients (8 children and 33 adults), 98% of patients who received a single dose of the C1-esterase inhibitor did not have an acute attack of angioedema within 72 hours.1

The C1-esterase inhibitor demonstrated efficacy in routine prevention in a double-blind, placebo-controlled crossover study in 22 patients over a 24-week period. The number of attacks per 12-week period was reduced by half in patients who received prophylactic C1-esterase inhibitor compared with those who received placebo (6.26 vs 12.73, p<0.0001).2

Cinryze is licensed only for use in adults and adolescents and not in children.

Other treatment options

Current options for the treatment of acute attacks of angioedema include another human-plasma-derived C1-esterase inhibitor product (Berinert) and a C1-esterase inhibitor analogue produced from transgenic rabbits, conestat alfa (Ruconest); however, neither product is licensed for pre-procedure or routine prevention.


  1. Zuraw BL, et al. N Engl J Med 2010; 363: 513–22.
  2. Lumry W et al. Poster presented at American Academy of Allergy Asthma & Immunology Annual Meeting, San Francisco, USA, March 2011: P903.

View Cinryze drug record

Further information: ViroPharma Ltd

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more